APA (7th ed.) Citation

M, M., IA, D., A, M., A, E., R, M., S, B., . . . H, K. (2026). Immunogenicity and safety of Papilloguard® 4, the first quadrivalent HPV vaccine combined with adjuvant system 04, versus Gardasil® in healthy 15-25-year-old individuals: A phase III, randomized, double-blind, non-inferiority trial. Vaccine, 88, 128886. https://doi.org/10.1016/j.vaccine.2026.128886

Chicago Style (17th ed.) Citation

M, Mardani, et al. "Immunogenicity and Safety of Papilloguard® 4, the First Quadrivalent HPV Vaccine Combined with Adjuvant System 04, Versus Gardasil® in Healthy 15-25-year-old Individuals: A Phase III, Randomized, Double-blind, Non-inferiority Trial." Vaccine 88 (2026): 128886. https://doi.org/10.1016/j.vaccine.2026.128886.

MLA (9th ed.) Citation

M, Mardani, et al. "Immunogenicity and Safety of Papilloguard® 4, the First Quadrivalent HPV Vaccine Combined with Adjuvant System 04, Versus Gardasil® in Healthy 15-25-year-old Individuals: A Phase III, Randomized, Double-blind, Non-inferiority Trial." Vaccine, vol. 88, 2026, p. 128886, https://doi.org/10.1016/j.vaccine.2026.128886.